glp 1 and medicaid Navigating Changes to GLP-1 Medication Coverage GLP-1s and The Payer Predicament

Bornstein SR, Allolio B, Arlt W, et al

There have been reports of acute pancreatitis in patients taking semaglutide during premarketing trials

J.HungK

The primary outcomes were safety and tolerability, assessed by the incidence, severity, and causality of adverse events and by changes in clinical laboratory parameters and physical examinations

Critical evaluation of receptivity testing illustrates that distinguishing timing misalignment from intrinsic endometrial dysfunction requires multi-layer endotyping beyond transcriptomics alone, while embryo selection benefits from combining metabolic efficiency readouts with morphokinetic parameters and stress response signatures

However, the critical limitation remains the near-complete absence of human clinical trial data